FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283695411> ?p ?o ?g. }

• W4283695411 endingPage "1191" @default.
• W4283695411 startingPage "1191.2" @default.
• W4283695411 abstract "Background SLAMF7 (CD319, CS1) is a lymphocyte signaling activation molecule (SLAM) belonging to the CD2 receptor family. It regulates many immune functions following its activation by homotypic interaction (SLAMF7 as ligand and receptor). Its expression is observed on different hematopoietic cells such as plasma cells and NK cells and its activation leads to increased cytotoxic degranulation and IFNg secretion. SLAMF7 is a therapeutic target in multiple myeloma where plasma cells over-express SLAMF7. Elotuzumab, which binds to SLAMF7, induces an antibody-mediated cytotoxicity mechanism and an increase in the anti-tumor activity of NK cells. Objectives We investigated SLAMF7 expression in primary Sjögren’s syndrome (pSS). Methods SLAMF7 expression was studied using flow cytometry on different subpopulations (CD4 T cells, CD8 T cells, NK cells, plasma cells (CD19+ CD38+ CD27high) and naive (CD27-) or mature (CD27+) B cells before (IgD+) or after (IgD-) class switching in pSS patients and healthy donors (HD). SLAMF7 protein expression was measured by the difference in expression (condition with antibody recognizing SLAMF7 - condition without antibody) of the mean fluorescence intensity (delta MFI). Results The pSS cohort consisted of 18 patients (17 women). 71% of patients were anti-SSA+, 41% anti-SSB+, 44% had rheumatoid factors (RF). The median IgG level was 13.3 g/l (9.88-21.45). 8/18 patients had evidence of systemic activity (ESSDAI score >0). Twenty-one healthy donors (19 women) were used as controls. No overall difference in SLAMF7 expression was observed between pSS and healthy donors, or among pSS patients between patients with or without systemic complications. SLAMF7 expression was higher in patients with than in patients without autoantibodies or markers of B-cell activation. 1/RF-positive patients had a higher expression of SLAMF7 than RF-negative patients by IgD- CD27+ B cells (median delta MFI: 397 for RF+ pSS vs 185 for RF- negative pSS [p=0.001] vs 187 [p<0.0001] for HD) and by C27+ IgD+ B cells (median delta MFI: 450 for RF+ pSS vs 307 for RF- negative pSS [p=0.005] vs 329 [p=0.001] for HD). 2/ Anti-SSA-positive patients had a higher expression of SLAMF7 than anti-SSA-negative patients by CD27+ IgD- B cells (median delta MFI: 346 for anti-SSA+ pSS vs 149 for anti-SSA-negative pSS [p=0.019] vs 187 [p=0.007] for HD) and by C27+ IgD+ B cells (median delta MFI: 403 for anti-SSA+ pSS vs 264 for anti- SSA negative pSS [p=0.021] vs 329 [p=0.012] for HD). The same association with a higher expression of SLAMF7 was observed for anti-SSB. 3/SLAMF7 expression was correlated with IgG levels in pSS patients on IgD- CD27+ B cells (r=0.51, p=0.044). Conclusion This study shows for the first time an overexpression of SLAMF7 on the surface of mature B cells in patients with pSS. This overexpression of SLAMF7 is associated with the presence of markers of B-cell activation. The therapeutic targeting of SLAMF7 therefore deserves further investigation in pSS. A study of its expression in the target tissue of the disease, minor accessory salivary glands, will allow a more precise analysis of the potential pathogenic role of SLAMF7 in pSS. Acknowledgements Necessity project Disclosure of Interests None declared" @default.
• W4283695411 created "2022-06-30" @default.
• W4283695411 creator A5023887948 @default.
• W4283695411 creator A5027444891 @default.
• W4283695411 creator A5036698968 @default.
• W4283695411 creator A5037814320 @default.
• W4283695411 creator A5067579240 @default.
• W4283695411 date "2022-05-23" @default.
• W4283695411 modified "2023-09-25" @default.
• W4283695411 title "AB0121 STUDY OF SLAMF7 EXPRESSION IN PRIMARY GOUGEROT-SJÖGREN SYNDROME" @default.
• W4283695411 doi "https://doi.org/10.1136/annrheumdis-2022-eular.4370" @default.
• W4283695411 hasPublicationYear "2022" @default.
• W4283695411 type Work @default.
• W4283695411 citedByCount "0" @default.
• W4283695411 crossrefType "journal-article" @default.
• W4283695411 hasAuthorship W4283695411A5023887948 @default.
• W4283695411 hasAuthorship W4283695411A5027444891 @default.
• W4283695411 hasAuthorship W4283695411A5036698968 @default.
• W4283695411 hasAuthorship W4283695411A5037814320 @default.
• W4283695411 hasAuthorship W4283695411A5067579240 @default.
• W4283695411 hasBestOaLocation W42836954111 @default.
• W4283695411 hasConcept C10205521 @default.
• W4283695411 hasConcept C126322002 @default.
• W4283695411 hasConcept C159654299 @default.
• W4283695411 hasConcept C159912055 @default.
• W4283695411 hasConcept C167672396 @default.
• W4283695411 hasConcept C203014093 @default.
• W4283695411 hasConcept C2778453870 @default.
• W4283695411 hasConcept C2778957590 @default.
• W4283695411 hasConcept C28328180 @default.
• W4283695411 hasConcept C48010095 @default.
• W4283695411 hasConcept C502942594 @default.
• W4283695411 hasConcept C54355233 @default.
• W4283695411 hasConcept C71924100 @default.
• W4283695411 hasConcept C86803240 @default.
• W4283695411 hasConcept C8891405 @default.
• W4283695411 hasConceptScore W4283695411C10205521 @default.
• W4283695411 hasConceptScore W4283695411C126322002 @default.
• W4283695411 hasConceptScore W4283695411C159654299 @default.
• W4283695411 hasConceptScore W4283695411C159912055 @default.
• W4283695411 hasConceptScore W4283695411C167672396 @default.
• W4283695411 hasConceptScore W4283695411C203014093 @default.
• W4283695411 hasConceptScore W4283695411C2778453870 @default.
• W4283695411 hasConceptScore W4283695411C2778957590 @default.
• W4283695411 hasConceptScore W4283695411C28328180 @default.
• W4283695411 hasConceptScore W4283695411C48010095 @default.
• W4283695411 hasConceptScore W4283695411C502942594 @default.
• W4283695411 hasConceptScore W4283695411C54355233 @default.
• W4283695411 hasConceptScore W4283695411C71924100 @default.
• W4283695411 hasConceptScore W4283695411C86803240 @default.
• W4283695411 hasConceptScore W4283695411C8891405 @default.
• W4283695411 hasIssue "Suppl 1" @default.
• W4283695411 hasLocation W42836954111 @default.
• W4283695411 hasOpenAccess W4283695411 @default.
• W4283695411 hasPrimaryLocation W42836954111 @default.
• W4283695411 hasRelatedWork W1572283981 @default.
• W4283695411 hasRelatedWork W2084547554 @default.
• W4283695411 hasRelatedWork W2434372360 @default.
• W4283695411 hasRelatedWork W2621636529 @default.
• W4283695411 hasRelatedWork W271486173 @default.
• W4283695411 hasRelatedWork W2803613523 @default.
• W4283695411 hasRelatedWork W3048051248 @default.
• W4283695411 hasRelatedWork W3118284167 @default.
• W4283695411 hasRelatedWork W4220879180 @default.
• W4283695411 hasRelatedWork W4285831894 @default.
• W4283695411 hasVolume "81" @default.
• W4283695411 isParatext "false" @default.
• W4283695411 isRetracted "false" @default.
• W4283695411 workType "article" @default.